Drug Trial Radar · NCT03927703
A Phase 3 Efficacy & Safety of SB206 & Vehicle Gel for the Treatment of MC
Last checked: Nov 19, 2026Latest source record: Mar 23, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
355
Actual
Start
Jun 13, 2019
Primary completion
Nov 11, 2019
Study completion Feb 3, 2020
Sponsor
- Lead sponsor
- Novan, Inc.Industry
- Sponsor type
- Industry
- Collaborators
- Synteract, Inc.
- First posted
- Apr 25, 2019
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 6 months
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 3 multi-center, randomized, double-blind, vehicle-controlled, parallel group study to be conducted in up to approximately 340 subjects ≥6 months of age with MC. Subjects or their caregivers will apply SB206 12% or Vehicle Gel once daily for a minimum of 4 weeks and up to 12 weeks to all lesions identified at Baseline and new treatable lesions that arise during the course of the study.
Conditions
- Molluscum Contagiosum
Interventions
SB206 12%Drug
Topically once daily
PlaceboDrug
Topically once daily
Primary outcomes
What the sponsor says the trial is designed to measure.
- Complete Clearance of All Treatable MC at Week 12Time frame: 12 Weeks
Locations
27 sites in 1 country. Site status is shown where the registry gives one.
Site #266
Scottsdale, Arizona
Site #101
Hot Springs, Arkansas
Site #282
Beverly Hills, California
Site #113
San Diego, California
Site #257
Thornton, Colorado
Site #268
Boynton Beach, Florida
Site #292
DeLand, Florida
Site #278
Miami, Florida
Site #305
Tampa, Florida
Site #175
New Albany, Indiana
Site #294
Owensboro, Kentucky
Site #289
Metairie, Louisiana
Site #297
New Orleans, Louisiana
Site #275
Largo, Maryland
Site #274
Clarkston, Michigan
Site #121
Fridley, Minnesota
Site #206
Omaha, Nebraska
Site #304
Portsmouth, New Hampshire
Site #201
Berlin, New Jersey
Site #108
Rochester, New York
Site #309
Portland, Oregon
Site #255
Mt. Pleasant, South Carolina
Site #271
Knoxville, Tennessee
Site #167
Houston, Texas
Site #293
Plano, Texas
Site #281
Syracuse, Utah
Site #267
Richmond, Virginia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.